CC
EW icon

Capital Counsel’s Edwards Lifesciences EW Stock Holding History

Capital Counsel’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,750
Closed -$329K – 53
2023
Q3 		$329K Sell
4,750
-1,100
-19% -$88.4K 0.02% 41
2023
Q2 		$552K Buy
5,850
+1,100
+23% +$95.6K 0.03% 34
2023
Q1 		$393K Sell
4,750
-700
-13% -$55K 0.02% 38
2022
Q4 		$407K Sell
5,450
-825,854
-99% -$63.6M 0.03% 42
2022
Q3 		$68.7M Buy
831,304
+29,564
+4% +$2.84M 4.45% 10
2022
Q2 		$76.2M Sell
801,740
-262,179
-25% -$27.1M 4.65% 10
2022
Q1 		$125M Buy
1,063,919
+227,722
+27% +$25.5M 5.95% 9
2021
Q4 		$108M Buy
836,197
+479,749
+135% +$56M 4.59% 11
2021
Q3 		$40.4M Buy
+356,448
New +$40.7M 1.99% 13

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Capital Counsel's EW Position: Q4 2023 in Review

Capital Counsel sold out of Edwards Lifesciences (EW) in Q4 2023, closing a stake of 4,750 shares — an estimated $329K sold.

Capital Counsel first reported a position in EW in Q3 2021 and held it in 9 quarters. The position peaked at $125M in Q1 2022. 1,245 funds tracked by Wall St. Rank hold EW as of Q4 2023.

  • Capital Counsel reported no remaining Edwards Lifesciences position as of Q4 2023 after selling out during the quarter.
  • Capital Counsel sold 4,750 Edwards Lifesciences shares in Q4 2023, an estimated $329K.
  • Capital Counsel first reported a position in Edwards Lifesciences in Q3 2021 and held it in 9 quarters.
  • Capital Counsel's Edwards Lifesciences position peaked at $125M in Q1 2022.
  • 1,245 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2023.

Based on Capital Counsel's 13F filing for Q4 2023, filed 14 Feb 2024.